Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs doxazosin for ureteral stent-related symptoms
ChiCTR2500095161Phase 4Completed
- Sponsor
- Kunming Health Commission
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in ureteral stent-related symptoms (USRS) comparing mirabegron arm with doxazosin arm (2 arms). Primary endpoint: Ureteral stent symptoms (USSQ, IPSS, VAS). Started Jan 2025; status: completed.
02
Drugs
mirabegrondoxazosin
03
Conditions
ureteral stent-related symptoms (USRS)
Beyond the preview
Go deeper on ChiCTR2500095161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095161.